MCS Medical Compression Systems (DBN) Ltd. (TASE:MDCL) today announced that, during August, four more medical centers in the US chose the company's proprietary ActiveCare + SFT non-invasive device for the treatment of deep vein thrombosis. The medical centers are in Indiana, Minnesota, and Missouri.
MCS's share price rose 8.4% by mid-afternoon to NIS 3.56, giving a market cap of NIS 124 million.
MCS said that the four medical centers carry out 4,600 deep vein thrombosis procedures a year, and that the company's product will achieve a 25% penetration rate in the first year.
MCS CEO Adi Dagan said, "Without a doubt, the company is consolidating its penetration and is encountering fewer and fewer barriers in sales to medical centers."
MCS's ActiveCare + SFT device has both US Food and Drug Administration (FDA) and EU CE Mark certification.
Published by Globes [online], Israel business news - www.globes-online.com - on September 6, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010